133 related articles for article (PubMed ID: 38811278)
1. Sacubitril/valsartan has an underestimated impact on the right ventricle in patients with sleep-disordered breathing, especially central sleep apnoea syndrome.
Cardelli LS; Magaldi M; Agullo A; Richard G; Nogue E; Berdague P; Galiner M; Georger F; Picard F; Prunet E; Molinari N; Bourdin A; Jaffuel D; Roubille F
Arch Cardiovasc Dis; 2024; 117(6-7):409-416. PubMed ID: 38811278
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
3. Do the remodeling effects of sacubitril/valsartan treatment depend upon heart failure duration?
Villani A; Ravaro S; Cerea P; Caravita S; Ciambellotti F; Branzi G; Munforti C; Parati G; Malfatto G
J Cardiovasc Med (Hagerstown); 2020 Sep; 21(9):682-687. PubMed ID: 32744827
[TBL] [Abstract][Full Text] [Related]
4. Impact of sacubitril-valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO-SAS study design.
Jaffuel D; Molinari N; Berdague P; Pathak A; Galinier M; Dupuis M; Ricci JE; Mallet JP; Bourdin A; Roubille F
ESC Heart Fail; 2018 Jun; 5(3):222-230. PubMed ID: 29469206
[TBL] [Abstract][Full Text] [Related]
5. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
Kang DH; Park SJ; Shin SH; Hong GR; Lee S; Kim MS; Yun SC; Song JM; Park SW; Kim JJ
Circulation; 2019 Mar; 139(11):1354-1365. PubMed ID: 30586756
[TBL] [Abstract][Full Text] [Related]
7. Left-Ventricular Function After 3 Months of Sacubitril-Valsartan in Acute Decompensated Heart Failure.
Mirić D; Baković D; Eterović D; Sorić T; Čapkun V; Vuković I; Duplančić D; Barac A
J Cardiovasc Transl Res; 2021 Apr; 14(2):290-298. PubMed ID: 32557158
[TBL] [Abstract][Full Text] [Related]
8. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
9. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
[TBL] [Abstract][Full Text] [Related]
10. Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
Pericas P; Mas-Lladó C; Ramis-Barceló MF; Valadrón I; Noris Mora M; Pasamar Márquez L; González Colino R; Forteza Albertí JF; Peral Disdier V; Rossello X
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):167-175. PubMed ID: 33599965
[TBL] [Abstract][Full Text] [Related]
11. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
13. Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
Dereli S; Bayramoğlu A; Kaya A
J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):13-20. PubMed ID: 31714330
[TBL] [Abstract][Full Text] [Related]
14. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
15. Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan.
Januzzi JL; Camacho A; Piña IL; Rocha R; Williamson KM; Maisel AS; Felker GM; Prescott MF; Butler J; Solomon SD;
Circ Heart Fail; 2020 Jun; 13(6):e006946. PubMed ID: 32482089
[No Abstract] [Full Text] [Related]
16. Comparison of the Effect of Sacubitril/Valsartan on Left Ventricular Systolic Function in Patients with Non-ischaemic and Ischaemic Cardiomyopathy.
Ioannou A; Metaxa S; Simon S; Mandal AKJ; Missouris CG
Cardiovasc Drugs Ther; 2020 Dec; 34(6):755-762. PubMed ID: 32648169
[TBL] [Abstract][Full Text] [Related]
17. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
18. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
[No Abstract] [Full Text] [Related]
19. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
[TBL] [Abstract][Full Text] [Related]
20. Echocardiographic evaluation of the effects of sacubitril-valsartan on vascular properties in heart failure patients.
Karagodin I; Kalantari S; Yu DB; Kim G; Sayer G; Addetia K; Tayazime S; Weinert L; Yamat M; Uriel N; Lang R; Mor-Avi V
Int J Cardiovasc Imaging; 2020 Feb; 36(2):271-278. PubMed ID: 31583499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
